Table 1.
General, anthropometric, hormonal, and metabolic parameters of the study population.
| 18.5 ≤ BMI< 25 | BMI ≥ 25 | P value | |
|---|---|---|---|
| (n = 820) | (n = 552) | ||
| General characteristics | |||
| Age (years) | 48.33 ± 9.28 | 48.64 ± 8.34 | 0.525 |
| Height (cm) | 167.56 ± 7.05 | 170.61 ± 6.08 | <0.001∗∗∗ |
| Body weight (kg) | 63.20 ± 8.00 | 79.52 ± 8.28 | <0.001∗∗∗ |
| BMI (kg/m2) | 22.43 ± 1.70 | 27.28 ± 1.96 | <0.001∗∗∗ |
| Lipid profile | |||
| TG (mmol/L) | 1.27(0.87–1.89) | 1.90 (1.32–2.86) | <0.001∗∗∗ |
| Total cholesterol (mmol/L) | 4.82 ± 0.96 | 4.95 ± 0.94 | <0.05∗ |
| HDL cholesterol (mg/L) | 13.21 ± 3.34 | 11.64 ± 2.95 | <0.001∗∗∗ |
| LDL cholesterol (mg/L) | 29.53 ± 8.18 | 29.93 ± 8.18 | 0.386 |
| TSH and thyroid hormones | |||
| FT3 (pmol/L) | 4.11 ± 0.57 | 4.29 ± 0.58 | <0.001∗∗∗ |
| FT4 (pmol/L) | 12.62 ± 1.70 | 12.41 ± 1.54 | <0.05∗ |
| TSH (mIU/L) | 1.66 ± 0.86 | 1.58 ± 0.85 | 0.074 |
Subjects on thyroid medications, with TPO antibodies, anti-thyroglobulin antibodies above clinical cutoff, and with TSH levels outside the reference range, were excluded from further analyses. We stratified the study group according to BMI levels: 18.5 ≤ BMI< 25 kg/m2: normal-weight group; BMI ≥ 25 kg/m2: overweight/obese group. All continuous parameters were presented as mean ± standard deviation. For skewness distribution data, median and interquartile range was used. P values were calculated from one-way analysis of variance. BMI: body mass index; FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyrotropin; TG: triglycerides; HDL: high-density lipoprotein; LDL: low-density lipoprotein. Significant associations are indicated in bold. P < 0.05 was considered statistically significant. ∗P < 0.05, ∗∗∗P < 0.001.